$VRTX · VERTEX PHARMACEUTICALS INC / MA
Vertex reported Q3 2026 revenue of $3.44B (+12% YoY), raised full-year revenue guidance to $13.15B–$13.25B, and posted GAAP diluted EPS of $2.56. GAAP net income dropped to $654M from $1.08B a year ago, driven by ~$500M in compensation and transaction costs tied to the Crinetics Pharmaceuticals acquisition. Non-GAAP net income held flat at $1.2B as product revenue growth was offset by higher operating expenses and interest costs.
- Total Q3 revenue rose 12% YoY to $3.44B, driven by CF portfolio and ALYFTREK ramp.
- GAAP net income fell 40% YoY to $654M, weighed by ~$500M in Crinetics acquisition compensation and transaction costs.
- FY2026 revenue guidance raised to $13.15B–$13.25B from $13.1B–$13.2B; combined GAAP opex guidance hiked to $7.15B–$7.2B.
- CASGEVY revenue hit $99M in Q3, up 30% QoQ and nearly 6x the $17M in Q3 2025.
- Povetacicept PDUFA date for IgAN is November 30, 2026 — potential fifth commercial franchise launch.
Extended-hours trading shows VRTX at $553.93, essentially flat (+0.14%) vs the regular close of $553.15. The market appears to be digesting the mixed picture: strong top-line growth and raised guidance offset by a sharp GAAP earnings decline and higher expense outlook tied to the Crinetics acquisition.
Vertex's earnings show a company in transition: legacy CF cash flows are funding an aggressive diversification push, but the Crinetics acquisition is materially compressing GAAP profits in the near term.
Vertex's diversification beyond CF is accelerating: non-CF products (CASGEVY, JOURNAVX, PALSONIFY) are scaling, and the pending povetacicept decision could open a fifth franchise in nephrology — a rare feat in large-cap biotech where pipeline concentration risk is a persistent overhang.
Combined GAAP R&D, AIPR&D, and SG&A expense guidance jumped to $7.15B–$7.2B from $6.3B–$6.45B, reflecting Crinetics integration costs and ~$500M in one-time compensation/transaction expenses. The $9.0B net cash used for the Crinetics deal and buybacks cut cash reserves from $12.3B to $9.8B, partially offset by $4.5B in new term loan debt.